內地中成藥聯採辦正式成立 首次集採涉16種藥品
為深入推進藥品集中帶量採購制度改革,根據《國務院辦公廳關於推動藥品集中帶量採購工作常態化制度化開展的意見》(國辦發(2021)2號)精神,由湖北省及北京市等聯盟地區委派代表組成全國中成藥聯合採購辦公室,在國家醫療保障局指導下,代表該地區相關醫藥機構開展中成藥及相關藥品集中帶量採購。
湖北省醫療保障局承擔聯合採購辦公室日常工作並負責具體實施。此次聯採辦針對16種中成藥進行集採。(ta/s) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.